Systems biology of pro‐angiogenic therapies targeting the VEGF system
- 7 April 2010
- journal article
- review article
- Published by Wiley in Wires Systems Biology and Medicine
- Vol. 2 (6), 694-707
- https://doi.org/10.1002/wsbm.92
Abstract
Vascular endothelial growth factor (VEGF) is a family of cytokines for which the dysregulation of expression is involved in many diseases; for some, excess VEGF causes pathological hypervascularization, while for others VEGF‐induced vascular remodeling may alleviate ischemia and/or hypoxia. Anti‐angiogenic therapies attacking the VEGF pathway have begun to live up to their promise for treatment of certain cancers and of age‐related macular degeneration. However, the corollary is not yet true: in coronary artery disease and peripheral artery disease, clinical trials of pro‐angiogenic VEGF delivery have not, so far, proven successful. The VEGF and VEGF‐receptor system is complex, with at least five ligand genes, some encoding multiple protein isoforms and five receptor genes. A systems biology approach for designing pro‐angiogenic therapies, using a combination of quantitative experimental approaches and detailed computational models, is essential to deal with this complexity and to understand the effects of drugs targeting the system. This approach allows us to learn from unsuccessful clinical trials and to design and test novel single therapeutics or combinations of therapeutics. Among the parameters that can be varied in order to determine optimal strategy are dosage, timing of multiple doses, route of administration, and the molecular target. Copyright © 2010 John Wiley & Sons, Inc. This article is categorized under: Models of Systems Properties and Processes > Organ, Tissue, and Physiological Models Analytical and Computational Methods > Computational Methods Translational, Genomic, and Systems Medicine > Translational MedicineThis publication has 103 references indexed in Scilit:
- Promoting angiogenesis via manipulation of VEGF responsiveness with notch signalingBiomaterials, 2009
- Gene regulation in response to graded hypoxia: The non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathwayJournal of Theoretical Biology, 2009
- VEGF Gene Therapy Fails to Improve Perfusion of Ischemic Myocardium in Patients With Advanced Coronary Disease: Results of the NORTHERN TrialMolecular Therapy, 2009
- Hypoxia inducible factor-2α: a critical mediator of aggressive tumor phenotypesCurrent Opinion in Genetics & Development, 2009
- A role for VEGF as a negative regulator of pericyte function and vessel maturationNature, 2008
- Plasma Levels of Soluble Tie2 and Vascular Endothelial Growth Factor Distinguish Critical Limb Ischemia From Intermittent Claudication in Patients With Peripheral Arterial DiseaseJournal of the American College of Cardiology, 2008
- Biology of hypoxia-inducible factor-2α in development and diseaseCell Death & Differentiation, 2008
- Three autocrine feedback loops determine HIF1α expression in chronic hypoxiaBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2006
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996